Nano nod for lab-on-a-chip

Apr 25, 2012 By Bryan Alary
The Domino technology uses a plastic chip that can perform 20 genetic tests from a single drop of blood.

You wouldn't know it from appearances, but a metal cube the size of a toaster, created at the University of Alberta, is capable of performing the same genetic tests as most fully equipped modern laboratories—and in a fraction of the time.

At its core is a small plastic chip developed with that holds the key to determining whether a patient is resistant to cancer drugs or has infections like malaria. The chip can also pinpoint infectious diseases in a herd of cattle.

Talk about thinking outside the box.

Dubbed the Domino, the technology—developed by a U of A research team—has the potential to revolutionize point-of-care medicine. The innovation has also earned Aquila Diagnostic Systems, the Edmonton-based nano startup that licensed the technology, a shot at $175,000 as a finalist for the TEC NanoVenturePrize award.

“We’re basically replacing millions of dollars of equipment that would be in a conventional, consolidated lab with something that costs pennies to produce and is field portable so you can take it where needed. That’s where this technology shines,” said Jason Acker, an associate professor of laboratory medicine and pathology at the U of A and chief technology officer with Aquila.

The Domino employs polymerase chain reaction technology used to amplify and detect targeted sequences of DNA, but in a miniaturized form that fits on a plastic chip the size of two postage stamps. The chip contains 20 gel posts—each the size of a pinhead—capable of identifying sequences of DNA with a single drop of blood.

This video is not supported by your browser at this time.

Each post performs its own genetic test, meaning you can not only find out whether you have malaria, but also determine the type of malaria and whether your DNA makes you resistant to certain antimalarial drugs. It takes less than an hour to process one chip, making it possible to screen large populations in a short time.

“That’s the real value proposition—being able to do multiple tests at the same time,” Acker said, adding that the Domino has been used in several recently published studies, showing similar accuracy to centralized labs.

The Domino effect: Personalized medicine

The Domino was developed by a team led by Linda Pilarski, an experimental oncologist with the Faculty of Medicine & Dentistry and a former Tier 1 Canada Research Chair in biomedical nanotechnology.

In 2008, her team received $5 million over five years from Alberta Innovates Health Solutions to perfect and commercialize the technology. As an oncologist, Pilarski is interested in its pharmacogenomic testing capabilities, such as determining whether breast cancer patients are genetically disposed to resist certain drugs.

“With most cancers you want to treat the patient with the most effective therapeutic as possible,” she said. “That’s what this does: it really enables personalized medicine. It will be able to test every patient at the right time, right in their doctor’s office. That’s currently not feasible because it’s too expensive.”

Along with its versatility, two key selling points are affordability and portability, with each portable box expected to cost about $5,000 and each chip a few dollars, says Aquila president David Alton. It’s also designed to be easy to use and rugged—important features for the livestock industry, the company’s first target market. The Domino will be put through trials within a year at one of the country’s largest feedlots in southern Alberta.

Alton credits Aquila’s relationship with the U of A, not just for the research but for the business relationship with TEC Edmonton that has helped the company license and patent Domino. TEC Edmonton is a joint venture between the U of A and Edmonton Economic Development Corporation with resources and expertise to help startups in the early stages of operations.

“We see a huge potential market for the technology and we’re looking at applying the technology developed here at the U of A to markets first in Alberta and then globally, to address important health issues here and throughout the world.”

Explore further: Innovative strategy to facilitate organ repair

Related Stories

Recommended for you

Innovative strategy to facilitate organ repair

Apr 18, 2014

A significant breakthrough could revolutionize surgical practice and regenerative medicine. A team led by Ludwik Leibler from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ...

Physicists create new nanoparticle for cancer therapy

Apr 16, 2014

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

THENAMEIS_____
not rated yet Apr 25, 2012
I remember Ray Kurzweil and Michio Kaku predicting such a thing, and behold, it is here!
The technological singularity maybe near indeed :D

More news stories

Making graphene in your kitchen

Graphene has been touted as a wonder material—the world's thinnest substance, but super-strong. Now scientists say it is so easy to make you could produce some in your kitchen.

Finnish inventor rethinks design of the axe

(Phys.org) —Finnish inventor Heikki Kärnä is the man behind the Vipukirves Leveraxe, which is a precision tool for splitting firewood. He designed the tool to make the job easier and more efficient, with ...

Poll: Big Bang a big question for most Americans

Few Americans question that smoking causes cancer. But they have more skepticism than confidence in global warming, the age of the Earth and evolution and have the most trouble believing a Big Bang created the universe 13.8 ...